1,4-dihydropyridine has been researched along with Recrudescence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fardal, Ø; Lygre, H | 1 |
| Achard, JM; Choukroun, G; Fournier, A; Godefroy, O; Messerli, F; Modeliar, SS; Wang, J | 1 |
1 trial(s) available for 1,4-dihydropyridine and Recrudescence
| Article | Year |
|---|---|
Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Blood Pressure; Calcium; Cardiovascular Diseases; Dihydropyridines; Humans; Prevalence; Recurrence; Risk; Stroke; Time Factors; Treatment Outcome | 2006 |
1 other study(ies) available for 1,4-dihydropyridine and Recrudescence
| Article | Year |
|---|---|
Management of periodontal disease in patients using calcium channel blockers - gingival overgrowth, prescribed medications, treatment responses and added treatment costs.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Chronic Periodontitis; Dihydropyridines; Drug Combinations; Drug Substitution; Female; Follow-Up Studies; Gingival Overgrowth; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oral Hygiene; Recurrence; Renin-Angiotensin System; Retreatment; Tooth Loss; Treatment Outcome | 2015 |